Search

Search Constraints

You searched for: Author/Creator van Schaik, Ivo N.

Search Results

1. 17. Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PATH study. Issue 3 (March 2020)

2. 18. Secondary endpoints (PATH extension study): Long-term outcomes of subcutaneous immunoglobulin IgPro20 in CIDP maintenance treatment. Issue 3 (March 2020)

3. 19. Pharmacokinetic modelling and simulation of flexible dosing regimens of subcutaneous immunoglobulin (IgPro20) in CIDP patients. Issue 3 (March 2020)

4. 21. Exposure-response of serum IgG levels and INCAT scores in CIDP patients receiving subcutaneous immunoglobulin (IgPro20). Issue 3 (March 2020)

5. Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Issue 2 (15th March 2022)

10. Drug‐induced cutaneous lupus erythematosus after immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a case series. Issue 3 (5th September 2017)